Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 107 | 2024 | 16764 | 6.700 |
Why?
|
South Africa | 60 | 2023 | 1743 | 4.630 |
Why?
|
Refugees | 10 | 2022 | 515 | 2.770 |
Why?
|
CD4 Lymphocyte Count | 26 | 2020 | 2602 | 2.280 |
Why?
|
Mobile Health Units | 4 | 2019 | 83 | 2.020 |
Why?
|
Anti-HIV Agents | 22 | 2023 | 4320 | 1.940 |
Why?
|
Mass Screening | 20 | 2019 | 5265 | 1.820 |
Why?
|
Contraception | 3 | 2021 | 344 | 1.690 |
Why?
|
Continuity of Patient Care | 8 | 2021 | 1054 | 1.620 |
Why?
|
Cryptococcus | 3 | 2021 | 29 | 1.510 |
Why?
|
Tuberculosis, Pulmonary | 6 | 2018 | 806 | 1.490 |
Why?
|
Antigens, Fungal | 3 | 2021 | 70 | 1.480 |
Why?
|
Ambulatory Care Facilities | 9 | 2022 | 928 | 1.380 |
Why?
|
Beauty Culture | 2 | 2019 | 41 | 1.360 |
Why?
|
Tuberculosis | 8 | 2023 | 1892 | 1.290 |
Why?
|
AIDS Serodiagnosis | 4 | 2014 | 202 | 1.260 |
Why?
|
Point-of-Care Systems | 6 | 2021 | 1175 | 1.180 |
Why?
|
Uganda | 18 | 2023 | 1230 | 1.170 |
Why?
|
Mycobacterium tuberculosis | 7 | 2019 | 1819 | 1.150 |
Why?
|
Lipopolysaccharides | 5 | 2018 | 2208 | 1.080 |
Why?
|
Sexually Transmitted Diseases | 4 | 2024 | 616 | 1.070 |
Why?
|
Chlamydia Infections | 3 | 2024 | 364 | 1.040 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2020 | 664 | 1.030 |
Why?
|
Gonorrhea | 3 | 2024 | 335 | 1.030 |
Why?
|
Anti-Retroviral Agents | 12 | 2022 | 1734 | 1.000 |
Why?
|
Sarcoma, Kaposi | 6 | 2022 | 365 | 0.970 |
Why?
|
Diagnostic Tests, Routine | 4 | 2015 | 789 | 0.940 |
Why?
|
Antiretroviral Therapy, Highly Active | 8 | 2020 | 1896 | 0.860 |
Why?
|
Patient Acceptance of Health Care | 9 | 2023 | 3021 | 0.830 |
Why?
|
Meningitis, Cryptococcal | 2 | 2021 | 64 | 0.820 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2022 | 3908 | 0.780 |
Why?
|
Reagent Kits, Diagnostic | 3 | 2018 | 230 | 0.760 |
Why?
|
Internationality | 2 | 2018 | 1004 | 0.740 |
Why?
|
Contraceptive Agents | 1 | 2021 | 144 | 0.720 |
Why?
|
Social Support | 5 | 2022 | 2112 | 0.720 |
Why?
|
Adult | 80 | 2023 | 213394 | 0.710 |
Why?
|
Community Health Services | 4 | 2021 | 652 | 0.690 |
Why?
|
HIV Seropositivity | 4 | 2013 | 966 | 0.630 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2022 | 2241 | 0.600 |
Why?
|
Prevalence | 18 | 2024 | 15153 | 0.590 |
Why?
|
Female | 88 | 2024 | 378853 | 0.580 |
Why?
|
Humans | 135 | 2024 | 739398 | 0.580 |
Why?
|
Male | 80 | 2023 | 349022 | 0.560 |
Why?
|
Qualitative Research | 9 | 2023 | 2656 | 0.560 |
Why?
|
Lost to Follow-Up | 2 | 2017 | 108 | 0.540 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 128 | 0.530 |
Why?
|
Public Sector | 1 | 2017 | 266 | 0.520 |
Why?
|
Hair | 1 | 2018 | 479 | 0.520 |
Why?
|
Maternal Mortality | 1 | 2018 | 312 | 0.520 |
Why?
|
Health Resources | 5 | 2014 | 920 | 0.520 |
Why?
|
Prospective Studies | 30 | 2023 | 53037 | 0.510 |
Why?
|
Viral Load | 6 | 2020 | 3299 | 0.510 |
Why?
|
Influenza Vaccines | 1 | 2022 | 740 | 0.500 |
Why?
|
Patient Transfer | 2 | 2019 | 763 | 0.500 |
Why?
|
Cryptococcosis | 1 | 2015 | 101 | 0.490 |
Why?
|
Postpartum Period | 2 | 2018 | 1070 | 0.490 |
Why?
|
HIV-1 | 8 | 2020 | 6931 | 0.490 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4374 | 0.490 |
Why?
|
Voluntary Programs | 3 | 2014 | 45 | 0.460 |
Why?
|
Sputum | 6 | 2018 | 474 | 0.460 |
Why?
|
Case Management | 2 | 2021 | 287 | 0.460 |
Why?
|
Medically Underserved Area | 1 | 2015 | 254 | 0.450 |
Why?
|
Geographic Information Systems | 1 | 2015 | 281 | 0.450 |
Why?
|
Trichomonas Infections | 2 | 2023 | 43 | 0.440 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 429 | 0.430 |
Why?
|
Young Adult | 31 | 2023 | 56255 | 0.430 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2014 | 326 | 0.420 |
Why?
|
HIV | 6 | 2022 | 1607 | 0.420 |
Why?
|
Health Services Research | 2 | 2017 | 1832 | 0.410 |
Why?
|
Forecasting | 1 | 2020 | 2952 | 0.390 |
Why?
|
Influenza, Human | 1 | 2022 | 1476 | 0.380 |
Why?
|
HIV Seroprevalence | 1 | 2011 | 87 | 0.380 |
Why?
|
Outpatients | 4 | 2021 | 1469 | 0.380 |
Why?
|
Rural Population | 3 | 2023 | 2181 | 0.380 |
Why?
|
Counseling | 4 | 2023 | 1526 | 0.380 |
Why?
|
Social Stigma | 6 | 2022 | 695 | 0.370 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7897 | 0.360 |
Why?
|
Delivery of Health Care | 7 | 2023 | 5272 | 0.360 |
Why?
|
Behavior Therapy | 1 | 2015 | 865 | 0.350 |
Why?
|
Focus Groups | 3 | 2022 | 1308 | 0.350 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 277 | 0.350 |
Why?
|
Health Services Accessibility | 4 | 2017 | 5128 | 0.340 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2018 | 2028 | 0.340 |
Why?
|
Placenta Diseases | 2 | 2021 | 194 | 0.330 |
Why?
|
Medical Assistance | 1 | 2008 | 104 | 0.320 |
Why?
|
Sensitivity and Specificity | 9 | 2021 | 14740 | 0.310 |
Why?
|
Adolescent | 27 | 2023 | 85405 | 0.300 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 3844 | 0.300 |
Why?
|
Trust | 2 | 2022 | 502 | 0.300 |
Why?
|
Motivation | 2 | 2023 | 1965 | 0.300 |
Why?
|
RNA, Viral | 4 | 2015 | 2907 | 0.290 |
Why?
|
Contact Tracing | 3 | 2024 | 273 | 0.280 |
Why?
|
Middle Aged | 33 | 2023 | 212863 | 0.280 |
Why?
|
Patient Satisfaction | 3 | 2015 | 3382 | 0.280 |
Why?
|
Homosexuality, Male | 3 | 2023 | 1239 | 0.280 |
Why?
|
Cross-Sectional Studies | 10 | 2022 | 24714 | 0.270 |
Why?
|
Serologic Tests | 2 | 2019 | 373 | 0.270 |
Why?
|
Government Programs | 1 | 2007 | 277 | 0.260 |
Why?
|
Cohort Studies | 16 | 2023 | 40389 | 0.260 |
Why?
|
Kenya | 6 | 2022 | 678 | 0.250 |
Why?
|
Family Characteristics | 2 | 2023 | 997 | 0.250 |
Why?
|
Sexual Partners | 3 | 2024 | 727 | 0.240 |
Why?
|
Needlestick Injuries | 1 | 2004 | 68 | 0.240 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2012 | 909 | 0.240 |
Why?
|
Hypothermia | 2 | 2022 | 188 | 0.230 |
Why?
|
Blood Sedimentation | 2 | 2022 | 232 | 0.230 |
Why?
|
Feasibility Studies | 3 | 2018 | 5058 | 0.220 |
Why?
|
Subacute Care | 2 | 2023 | 168 | 0.220 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2022 | 425 | 0.210 |
Why?
|
Medication Adherence | 3 | 2018 | 2047 | 0.200 |
Why?
|
Syphilis | 1 | 2024 | 225 | 0.200 |
Why?
|
Pandemics | 6 | 2023 | 8274 | 0.200 |
Why?
|
Fluconazole | 1 | 2021 | 145 | 0.200 |
Why?
|
Drug Users | 1 | 2022 | 132 | 0.190 |
Why?
|
Placenta | 4 | 2023 | 1682 | 0.190 |
Why?
|
Pregnancy | 12 | 2024 | 29002 | 0.190 |
Why?
|
Health Behavior | 1 | 2012 | 2624 | 0.190 |
Why?
|
Directly Observed Therapy | 1 | 2021 | 137 | 0.190 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2017 | 563 | 0.190 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2022 | 606 | 0.180 |
Why?
|
Africa South of the Sahara | 5 | 2024 | 727 | 0.180 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15511 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 163 | 0.180 |
Why?
|
Thoracostomy | 1 | 2019 | 72 | 0.170 |
Why?
|
Pharmacies | 1 | 2021 | 150 | 0.170 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 25 | 0.170 |
Why?
|
Puerperal Infection | 1 | 2018 | 47 | 0.160 |
Why?
|
Immunologic Tests | 1 | 2019 | 104 | 0.160 |
Why?
|
Retrospective Studies | 15 | 2023 | 76631 | 0.160 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 7726 | 0.160 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 128 | 0.160 |
Why?
|
Nigeria | 5 | 2020 | 730 | 0.160 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 523 | 0.150 |
Why?
|
Viremia | 2 | 2022 | 733 | 0.150 |
Why?
|
DNA, Bacterial | 2 | 2014 | 1467 | 0.150 |
Why?
|
Acinetobacter | 1 | 2017 | 39 | 0.150 |
Why?
|
Cost-Benefit Analysis | 5 | 2022 | 5462 | 0.150 |
Why?
|
Interviews as Topic | 2 | 2015 | 2533 | 0.150 |
Why?
|
Risk Factors | 14 | 2023 | 71974 | 0.150 |
Why?
|
Regression Analysis | 3 | 2016 | 6452 | 0.140 |
Why?
|
Acinetobacter Infections | 1 | 2017 | 68 | 0.140 |
Why?
|
Antifungal Agents | 1 | 2021 | 722 | 0.140 |
Why?
|
Hospitals, General | 1 | 2020 | 744 | 0.140 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 566 | 0.140 |
Why?
|
Safety | 1 | 2021 | 1186 | 0.140 |
Why?
|
Cephalosporins | 1 | 2017 | 204 | 0.140 |
Why?
|
Occupational Diseases | 1 | 2004 | 1474 | 0.140 |
Why?
|
Pneumothorax | 1 | 2019 | 379 | 0.140 |
Why?
|
Obesity | 4 | 2022 | 12643 | 0.130 |
Why?
|
Social Environment | 1 | 2020 | 1014 | 0.130 |
Why?
|
Mental Disorders | 1 | 2015 | 6570 | 0.130 |
Why?
|
Pilot Projects | 2 | 2019 | 8275 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12328 | 0.130 |
Why?
|
Prenatal Care | 1 | 2022 | 1087 | 0.130 |
Why?
|
Patient Compliance | 3 | 2017 | 2679 | 0.130 |
Why?
|
Logistic Models | 4 | 2020 | 13402 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2514 | 0.130 |
Why?
|
Random Allocation | 1 | 2019 | 2417 | 0.130 |
Why?
|
Disclosure | 1 | 2020 | 735 | 0.120 |
Why?
|
Public-Private Sector Partnerships | 1 | 2015 | 120 | 0.120 |
Why?
|
Violence | 1 | 2020 | 907 | 0.120 |
Why?
|
Primary Health Care | 2 | 2021 | 4537 | 0.120 |
Why?
|
Odds Ratio | 4 | 2020 | 9846 | 0.120 |
Why?
|
Income | 1 | 2023 | 1877 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 603 | 0.120 |
Why?
|
Interpersonal Relations | 1 | 2021 | 1421 | 0.120 |
Why?
|
Caregivers | 2 | 2017 | 2067 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2021 | 1152 | 0.110 |
Why?
|
Geography | 2 | 2013 | 672 | 0.110 |
Why?
|
Patient Discharge | 2 | 2023 | 3286 | 0.110 |
Why?
|
Depression | 1 | 2012 | 7689 | 0.110 |
Why?
|
Streptomycin | 1 | 2012 | 70 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1262 | 0.110 |
Why?
|
Kanamycin | 1 | 2012 | 65 | 0.110 |
Why?
|
Immunoenzyme Techniques | 2 | 2019 | 1801 | 0.110 |
Why?
|
Ethambutol | 1 | 2012 | 62 | 0.110 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1407 | 0.110 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3752 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2020 | 2303 | 0.110 |
Why?
|
Hepatitis C | 1 | 2022 | 1580 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2018 | 961 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
United States | 8 | 2022 | 69573 | 0.100 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3510 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19811 | 0.100 |
Why?
|
Urinalysis | 1 | 2014 | 370 | 0.100 |
Why?
|
Public Health Administration | 1 | 2013 | 241 | 0.100 |
Why?
|
Inflammation | 2 | 2021 | 10534 | 0.100 |
Why?
|
Hospitals, Rural | 1 | 2012 | 171 | 0.100 |
Why?
|
Algorithms | 3 | 2018 | 13872 | 0.100 |
Why?
|
Antitubercular Agents | 2 | 2019 | 1311 | 0.100 |
Why?
|
Isoniazid | 1 | 2012 | 271 | 0.100 |
Why?
|
Gene Products, gag | 1 | 2011 | 337 | 0.100 |
Why?
|
Aged | 13 | 2022 | 162698 | 0.090 |
Why?
|
Stereotyping | 1 | 2012 | 240 | 0.090 |
Why?
|
Rifampin | 1 | 2012 | 314 | 0.090 |
Why?
|
Hospitals, Urban | 1 | 2012 | 503 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3672 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2020 | 5305 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3232 | 0.090 |
Why?
|
Vulnerable Populations | 1 | 2015 | 685 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 554 | 0.090 |
Why?
|
Drug Administration Routes | 1 | 2010 | 154 | 0.090 |
Why?
|
Hospitalization | 5 | 2021 | 10208 | 0.090 |
Why?
|
False Negative Reactions | 1 | 2011 | 589 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2017 | 2448 | 0.090 |
Why?
|
Program Evaluation | 2 | 2015 | 2484 | 0.090 |
Why?
|
Developing Countries | 2 | 2012 | 2779 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2478 | 0.080 |
Why?
|
Child | 8 | 2022 | 77033 | 0.080 |
Why?
|
Incidence | 4 | 2023 | 20913 | 0.080 |
Why?
|
Cell Count | 1 | 2013 | 1833 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12237 | 0.080 |
Why?
|
Sex Factors | 2 | 2021 | 10398 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2011 | 2711 | 0.080 |
Why?
|
Medical Record Linkage | 1 | 2010 | 285 | 0.080 |
Why?
|
Prejudice | 1 | 2012 | 572 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2020 | 3514 | 0.080 |
Why?
|
Massachusetts | 4 | 2022 | 8669 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2851 | 0.080 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 877 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1735 | 0.070 |
Why?
|
Peer Group | 2 | 2023 | 635 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3029 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1420 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2019 | 38942 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3722 | 0.070 |
Why?
|
Infant, Newborn | 6 | 2023 | 25470 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5941 | 0.070 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5702 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1108 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4239 | 0.070 |
Why?
|
Urban Health | 1 | 2008 | 547 | 0.070 |
Why?
|
Infant | 4 | 2022 | 34923 | 0.070 |
Why?
|
Health Personnel | 2 | 2012 | 3203 | 0.070 |
Why?
|
Microscopy | 1 | 2010 | 899 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2007 | 392 | 0.060 |
Why?
|
Survival Analysis | 2 | 2019 | 10247 | 0.060 |
Why?
|
Urban Population | 1 | 2012 | 2014 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1321 | 0.060 |
Why?
|
Self Care | 1 | 2009 | 787 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2020 | 4426 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2974 | 0.060 |
Why?
|
Clinical Competence | 1 | 2019 | 4671 | 0.060 |
Why?
|
Health Care Costs | 2 | 2014 | 3226 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18349 | 0.060 |
Why?
|
Europe | 1 | 2010 | 3331 | 0.060 |
Why?
|
Acute Disease | 2 | 2011 | 7128 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2275 | 0.060 |
Why?
|
Blood Pressure | 1 | 2019 | 8554 | 0.060 |
Why?
|
Hospitals | 1 | 2017 | 3916 | 0.060 |
Why?
|
Fever | 2 | 2022 | 1607 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5181 | 0.060 |
Why?
|
New Mexico | 1 | 2022 | 86 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2723 | 0.050 |
Why?
|
Decision Trees | 1 | 2004 | 507 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1828 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 193 | 0.050 |
Why?
|
Disease Progression | 2 | 2023 | 13237 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3524 | 0.050 |
Why?
|
Asthma | 1 | 2020 | 5950 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2022 | 57650 | 0.050 |
Why?
|
Bleomycin | 1 | 2022 | 496 | 0.050 |
Why?
|
Child, Preschool | 4 | 2022 | 40802 | 0.050 |
Why?
|
Hypertension | 2 | 2019 | 8431 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3866 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5632 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6174 | 0.050 |
Why?
|
Etoposide | 1 | 2022 | 637 | 0.050 |
Why?
|
Postnatal Care | 1 | 2022 | 233 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3854 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15036 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2007 | 808 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 9812 | 0.050 |
Why?
|
Longitudinal Studies | 3 | 2023 | 13880 | 0.050 |
Why?
|
Vincristine | 1 | 2022 | 1038 | 0.050 |
Why?
|
Sirolimus | 1 | 2007 | 1559 | 0.040 |
Why?
|
Parity | 1 | 2022 | 930 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2004 | 829 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5761 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2022 | 582 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 589 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2021 | 438 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 28901 | 0.040 |
Why?
|
Pediatrics | 1 | 2013 | 3454 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1583 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 383 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1581 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4424 | 0.040 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 570 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 5959 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2022 | 1038 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1034 | 0.040 |
Why?
|
Rwanda | 1 | 2019 | 696 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2022 | 1465 | 0.040 |
Why?
|
Health Facilities | 1 | 2021 | 564 | 0.040 |
Why?
|
Aftercare | 1 | 2022 | 858 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 11699 | 0.040 |
Why?
|
Temperature | 1 | 2022 | 2202 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1262 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10362 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1524 | 0.030 |
Why?
|
Time Factors | 5 | 2020 | 40050 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9133 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2062 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1701 | 0.030 |
Why?
|
Mozambique | 1 | 2014 | 54 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2007 | 2945 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1689 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2015 | 181 | 0.030 |
Why?
|
Models, Theoretical | 2 | 2021 | 3609 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1066 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6478 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4143 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2040 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3526 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1197 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3194 | 0.030 |
Why?
|
Gene Products, nef | 1 | 2011 | 110 | 0.030 |
Why?
|
Infection Control | 1 | 2019 | 968 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3151 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 131 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4522 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3504 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2881 | 0.020 |
Why?
|
Dermatology | 1 | 2020 | 871 | 0.020 |
Why?
|
Length of Stay | 1 | 2023 | 6295 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2560 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2007 | 5401 | 0.020 |
Why?
|
Risk Assessment | 1 | 2010 | 23294 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3106 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 2946 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6722 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4935 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2656 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9314 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7274 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 10961 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5631 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2022 | 62693 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8039 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1650 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2011 | 1675 | 0.020 |
Why?
|
Smoking | 1 | 2021 | 8960 | 0.020 |
Why?
|
Life Expectancy | 1 | 2011 | 1208 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12655 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10142 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3193 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8613 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9782 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5113 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11410 | 0.010 |
Why?
|
Leukemia | 1 | 2007 | 1502 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 4768 | 0.010 |
Why?
|
Quality Improvement | 1 | 2012 | 3730 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15194 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8307 | 0.010 |
Why?
|
Animals | 1 | 2004 | 168368 | 0.010 |
Why?
|
Quality of Life | 1 | 2012 | 12640 | 0.010 |
Why?
|